Linzess denied as non-formulary by Aetna?

Aetna's specific coverage criteria for linzess are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Linzess as Non-Formulary

Aetna's prescription drug formulary — its approved list of covered medications — is updated periodically, and Linzess (linaclotide) may sit on a non-preferred tier or be excluded from your specific plan's formulary entirely. A non-formulary denial means Aetna will not cover the drug at the standard benefit level under your current plan year. This is one of the most common reasons patients are denied specialty GI medications.

## Why This Denial Is Appealable

Non-formulary denials are appealable on two tracks: a formulary exception request and a standard coverage appeal. For a formulary exception, you must show that all covered alternatives are contraindicated, have already failed, or are otherwise not clinically appropriate for this patient — and your prescriber must document that position. Separately, ACA §2719 external review rights apply when a non-formulary denial has a medical basis. ERISA §503 full-and-fair review applies to employer-sponsored plans. File the internal appeal within the deadline on your denial notice; external review must be requested within approximately four months of exhausting internal remedies. Expedited review is available for urgent situations.

## The Concrete Appeal Process

1. Obtain Aetna's current formulary for your specific plan and confirm which tier Linzess sits on or whether it is excluded. 2. Request a formulary exception through your prescriber — this is a formal request that Aetna cover a non-formulary drug because the formulary alternatives are clinically inappropriate. 3. File a standard coverage appeal simultaneously or as a follow-on if the exception is denied. 4. Request external review if the internal process is exhausted.

## Documentation to Gather

• List of formulary alternatives: obtain from Aetna the specific drugs on the formulary for IBS-C or CIC.
• Trial-and-failure history: for each formulary alternative, document the dates of use, the clinical response, and any adverse effects or reasons the drug was inadequate — with chart notes.
• Prescriber's exception letter: a letter explaining why each formulary alternative is not clinically appropriate and why Linzess is the medically necessary choice, referencing applicable gastroenterology guidelines by organization name.
• Diagnosis documentation: chart notes confirming the IBS-C or CIC diagnosis and severity.

## Criteria-Mapping Structure

Aetna's formulary exception process typically requires evidence for each alternative on the formulary. Create a table: column 1 is the formulary alternative drug name; column 2 is the date your patient tried it; column 3 is the documented outcome or adverse effect from the chart. Attach the supporting chart note for each row. This structured response directly addresses every requirement Aetna will evaluate and reduces the chance of a second denial on documentation grounds.